The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 90K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Legler, D. F.
Right arrow Articles by Moser, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Legler, D. F.
Right arrow Articles by Moser, B.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*OMIM
*Protein*UniGene
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1998/2/655/ $5.00
The Journal of Experimental Medicine, Volume 187, Number 4, February 16, 1998 655-660


Brief Definitive Reports

B Cell–attracting Chemokine 1, a Human CXC Chemokine Expressed in Lymphoid Tissues, Selectively Attracts B Lymphocytes via BLR1/CXCR5

Daniel F. Legler*, Marcel Loetscher*, Regula Stuber Roos*, Ian Clark-Lewis{ddagger}, Marco Baggiolini*, and Bernhard Moser*

From the * Theodor-Kocher Institute, University of Bern, CH-3000 Bern 9, Switzerland, and the {ddagger} Biomedical Research Center, University of British Columbia, Vancouver, BC V6T 1Z3 Canada

Although most leukocytes, T lymphocytes in particular, respond to several different chemokines, there is virtually no information on chemokine activities and chemokine receptors in B lymphocytes. A putative chemokine receptor, BLR1, that is expressed in Burkitt's lymphoma cells and B lymphocytes was cloned a few years ago. Deletion of the gene for BLR1 yielded mice with abnormal primary follicles and germinal centers of the spleen and Peyer's patches, reflecting the inability of B lymphocytes to migrate into B cell areas. By screening expressed sequence tag DNA sequences, we have identified a CXC chemokine, termed B cell–attracting chemokine 1 (BCA-1), that is chemotactic for human B lymphocytes. BCA-1 cDNA encodes a protein of 109 amino acids with a leader sequence of 22 residues. The mature protein shares 23–34% identical amino acids with known CXC chemokines and is constitutively expressed in secondary lymphoid organs. BCA-1 was chemically synthesized and tested for activity on murine pre–B cells 300-19 transfected with BLR1 and on human blood B lymphocytes. In transfected cells, BCA-1 induced chemotaxis and Ca2+ mobilization demonstrating that it acts via BLR1. Under the same conditions, no activity was obtained with 10 CXC and 19 CC chemokines, lymphotactin, neurotactin/fractalkine and several other peptide ligands. BCA-1 was also a highly effective attractant for human blood B lymphocytes (which express BLR1), but was inactive on freshly isolated or IL-2–stimulated T lymphocytes, monocytes, and neutrophils. In agreement with the nomenclature rules for chemokine receptors, we propose the term CXCR5 for BLR1. Together with the observed disturbance of B cell colonization in BLR1/ CXCR5-deficient mice, the present results indicate that chemotactic recruitment by locally produced BCA-1 is important for the development of B cell areas of secondary lymphoid tissues.


We thank Dr. Luca Piali for FACS® analysis of the cell populations, Dr. Beatrice Dewald for critical reading of the manuscript, and the "Hochschulstiftung" of the University of Bern (Bern, Switzerland) for financing a Master Cycler PCR instrument. Donor blood buffy coats were provided by the Swiss Central Laboratory Blood Transfusion Service, Bern, Switzerland.

This work was supported by grant 31-39744.93 of the Swiss National Science Fundation to M. Baggiolini and B. Moser, and the Protein Engineering Network of Centers of Excellence (PENCE), Canada (to I. Clark-Lewis). The Professor Max Cloëtta Foundation, Zürich, supports B. Moser with a career development award.

Address correspondence to Marco Baggiolini, Theodor-Kocher Institute, University of Bern, PO Box 99, CH-3000 Bern 9, Switzerland. Phone: 41-31-631-4141; Fax: 41-31-631-3799; E-mail: marco.baggiolini{at}tki.unibe.ch


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS